SynthesisOrthopadie (Heidelberg, Germany)2026
Autologous platelet concentrate augmentation in anterior cruciate ligament reconstruction: a level I evidence-based meta-analysis.
Synthesis in Orthopadie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnterior cruciate ligament (ACL) injuries are common in young active individuals and reconstruction remains the standard treatment. Recently, biological augmentation with autologous platelet concentrates (APC) has gained interest given the potential to enhance graft healing. This meta-analysis examined whether the use of APC improves patient-reported outcome measures (PROM) and reduces complications after ACL reconstruction.
methodsRandomized controlled trials (RCT) comparing standard ACL reconstruction with APC-augmented procedures were included. Eligible articles were peer-reviewed and published in English, German, Italian, French or Spanish. A systematic search of PubMed, Web of Science and Embase was performed in June 2025. Extracted data included demographics, follow-up and PROMs. Methodological quality was assessed using the Cochrane RoB2 tool. Meta-analyses were conducted with Review Manager 5.3, applying inverse variance and Mantel-Haenszel methods. A subgroup analysis was performed for platelet-rich plasma (PRP).
resultsA total of 14 RCTs comprising 869 patients met the inclusion criteria. Methodological quality was acceptable, with no study rated as having a high risk of bias. The mean follow-up was 12.2 ± 7.4 months. Baseline features and PROMs were comparable between groups. The use of APC augmentation significantly reduced anterior tibial laxity but the effect size was below the clinical threshold. No significant differences were observed in PROMs or revision rates.
conclusionThe current level of I evidence does not support APC augmentation as a means to improve short-term outcomes or reduce complications after ACL reconstruction; however, its safety profile and biological rationale justify further high-quality RCTs with standardized protocols and longer follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.